Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study

Paul W. Jones, Dave Singh, Eric D. Bateman, Alvar Agusti, Rosa Lamarca, Gonzalo De Miquel, Rosa Segarra, Cynthia Caractae, Esther Garcia Gi

    Research output: Contribution to journalArticlepeer-review

    Abstract

    The efficacy and safety of two doses of aclidinium bromide were evaluated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). In this 24-week, double-blind trial, patients were randomised to twice-daily aclidinium (200 mg or 400 mg) or placebo. The primary efficacy end-point was change in trough forced expiratory volume in 1 s (FEV1) at week 24. Other end-points included peak FEV1, health status (St George's Respiratory Questionnaire; SGRQ) and dyspnoea (Transitional Dyspnoea Index; TDI). Overall, 828 patients were randomised. At week 24, significant improvements from baseline were observed with aclidinium 200 mg and 400 mg versus placebo for trough FEV1 (99 and 128 mL; both p
    Original languageEnglish
    Pages (from-to)830-836
    Number of pages6
    JournalEuropean Respiratory Journal
    Volume40
    Issue number4
    DOIs
    Publication statusPublished - 1 Oct 2012

    Keywords

    • Anticholinergic
    • Bronchodilation
    • Dyspnoea
    • Exacerbations
    • Health status
    • Long-acting muscarinic antagonist

    Fingerprint

    Dive into the research topics of 'Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study'. Together they form a unique fingerprint.

    Cite this